Osiris Shares Increase on Approval for Stem-Cell Therapy
This article is for subscribers only.
Osiris Therapeutics Inc. rose after the company said it won the world’s first approval for a stem-cell drug, gaining clearance in Canada to sell Prochymal for a disease that can attack patients who received bone-marrow transplants.
Osiris climbed 5.5 percent to $5.55 at 4 p.m. New York time. The shares have lost 24 percent in the last 12 months.